A phase I study of capecitabine in combination with oral lencovorin in patients with intractable solid tumors

Clinical Cancer Research

Volumn 4, Issue 11, 1998, Pages 2755-2761

  Cassidy, Jim ^a   Dirix, Luc ^b   Bissett, Donald ^a   Reigner, Bruno ^c   Griffin, Tom ^d   Allman, David ^e   Osterwalder, Bruno ^e   Van Oosterom, Alan T ^b  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d HOFFMANN LA ROCHE INC   (United States)

^e IQVIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; FOLINIC ACID;

ARTICLE; BONE MARROW RESCUE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; TREATMENT OUTCOME; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; FEMALE; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASMS; TREATMENT OUTCOME;

EID: 0031724433     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Kono, A., Hara, Y., Sugata, S., Karube, Y., Matsushima, Y., and Ishitsuka, H. Activation of 5′-deoxy-5-fluorouridine by thymidine phosphorylase in human tumors. Chem. Pharm. Bull. (Tokyo), 31: 175-178, 1983.
2. Ishikawa, T., Utoh, M., Sawada, N., Nishida, M., Fukase, Y., Sekiguchi, F., and Ishitsuka, H. Tumor selective delivery of 5-Fura by capecitabine, a new oral fluoropyrimidine carbamate in human cancer xenografts. Biol. Pharm. Bull., in press, 1998.
3. Ishikawa, T., Sekiguchi, F., Fukase, Y., Sawada, N., and Ishitsuka, H. Positive correlation between efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehdyrogenase activites in tumors in human cancer xenoarafts. Cancer Res., 58: 685-690, 1998.
4. Cao, S., Lu, K., Ishitsuka, H., and Rustum Y. M. Antitumor efficacy of capecitabine against fluorouracil-sensitive and -resistant tumours. Proc. Am. Soc. Clin. Oncol., 16: 795, 1997.
5. Takebayashi, Y., Akiyama, S., Akiba, S., Yamada, K., Miyadera, K., Sumizawa, T., Yamada, Y., Murata, F., and Aikou, T. Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma. J. Natl. Cancer Inst., 88: 1110-1117, 1996.
6. The Meta-Analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J. Clin. Oncol., 16: 301-308, 1998.
7. Regazzoni, S., Pesce, G., Marini, G., Cavalli, F., and Goldhirsch, A. Low-dose continuous intravenous infusion of 5-fluorouracil for metastatic breast cancer. Ann. Oncol., 7: 807-813, 1996.
8. Anderson, N., and Lokich, J. Controversial issues in 5-fluorouracil infusion use. Cancer (Phila.), 70: 998-1002, 1992.
9. Budman, D. R., Meropol, N. J., Reigner, B., Creaven, P. J., Lichtman, S., Berghorn, E., Behr, J., Gordon, R. J., Osterwalder, B., and Griffin, T. A phase I study of continuous twice daily treatment with capecitabine in patients with advanced and/or metastatic solid tumors. J. Clin. Oncol., in press, 1998.
10. Mackean, M. J., Planting, A. S. T., Twelves, C. Schellens, H. M., Allman, D., Osterwalder, B.T Reigner, B., Griffin, T., Kaye, S. B., and Verweij, J. A phase I and pharmacologic study of intermittent twice daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J. Clin. Oncol., in press, 1998.
11. Kawashima, A., and Horii, I. Comparative 4-week oral toxicity study of capecitabine and 5′-DFUR in cynomolgus monkeys. Roche Research Report J-146′249, 1994. In: Investigational Drug Brochure. Capecitabine, 4th version. Basel, Switzerland: Hoffmann-La Roche Inc., 1997.
12. Poon, M. A., O'Connell, M. J., Moertel, C. G., Wieand, H. S., Cullinan, S. A., Everson, L. K., Krook, J. E., Mailliard, J. A., Laurie, J. A., Tschetter, L. K., et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J. Clin. Oncol., 7: 1407-1418, 1989.
13. Poon, M. A., O'Connell, M. J., Wieand, H. S., Krook, J. E., Gerstner, J. B., Tschetter, L, K., Levitt, R., Kardinal, C. G., and Mailliard, J. A. Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J. Clin. Oncol., 9: 1967-1972, 1991.
14. Buroker, T. R., O'Connell, M. J., Wieand, H. S., Krook, J. E., Gerstner, J. B., Mailliard, J. A., Schaeffer, P. L., Levitt, R., Kardinal, C. G., and Gesme, D. H., Jr. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J. Clin. Oncol., 12: 14-20, 1994.
15. Reigner, B., Verweij, J., Dirix, L., Cassidy, J., Twelves, C., Allman, D., Weidekamm, E., Roos, B., Banken, L., Utoh, M., and Osterwalder, B. Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients. Clin. Cancer Res., 4: 941-948, 1998.
16. ™ in colorectal cancer patients. Proc. Am. Soc. Clin. Oncol., 16: 227a, 1997.
17. ™ (capecitabine) in patients with advanced colorectal cancer. Proc. Am. Soc. Clin. Oncol., 16: 227a, 1997.
18. Twelves, C., Budman, D. R., Creaven, P. J., Schellens, J. H. M., Kuruma, I., Dumont, E., Osterwalder, B., and Reigner, B. G. Pharmacokinetics (PK) and pharmacodynamics (PD) of capecitabine in two Phase I studies. Proc. Am. Soc. Clin. Oncol., 75: 476, 1996.
19. 19F magnetic resonance spectroscopy in patients on a protracted venous infusion with or without interferon-α. Ann. Oncol., 7: 47-53, 1996.
20. Cao, S., Rustum, Y. M., and Spector, T. 5-Ethynyluracil (776C85): a potent modulator of the pharmacokinetics and antitumor efficacy of 5-FU. Proc. Natl. Acad. Sci. USA. 54: 1507-1510, 1994.
21. Pazdur, R. Phase II study of UFT plus leucovorin in colorectal cancer. Oncology (Basel), 54 (Suppl. 1): 19-23, 1997.